So, nasal vaccination with NKT-cell activation could provide a much-needed solution to the problem of inducing cross-protective immunity using vaccines comprised of viral antigens that differ from ...

GRI Bio bolsters IP portfolio with granting of two global patents for Europe & Japan: La Jolla, California Wednesday, April 2, 2025, 14:00 Hrs [IST] GRI Bio, Inc., a biotechnology ...

LA JOLLA, CA - GRI Bio, Inc. (NASDAQ: GRI), a biotechnology firm specializing in the development of Natural Killer T (NKT) cell modulators, announced today the granting of two significant global ...

Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of ...

The aggregate gross proceeds to the Company from the offering were approximately $5.0 million before deducting the placement agent's fees and other offering expenses payable by the Company. The ...

LA JOLLA, CA - GRI Bio, Inc. (NASDAQ: GRI), a biotechnology firm specializing in the development of Natural Killer T (NKT) cell modulators, announced today the granting of two significant global ...

(NASDAQ: GRI) ("GRI Bio” or the "Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT”) cell modulators for the treatment of inflammatory ... The Company ...